any previous ACC meeting. And the one that was featured -- with a new blood clot preventer from Bayer AG and Johnson & Johnson called Xarelto -- proved a failure in the population in which it was tested. Evidence of the rise of devices was everywhere....
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Devices to lead heart disease fight
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account